32826-84-9

Upstream product

• 620-51-9 N,N'-di(3-methylphenyl)thiourea 
• 79-11-8 chloroacetic acid 
• 32826-76-9 2-phenylimino-3-m-tolyl-thiazolidin-4-one 
• 57628-36-1 2-(4-nitro-phenylimino)-3-m-tolyl-thiazolidin-4-one 
• 621-40-9 (3-methylphenyl)thiourea 
• 1215-91-4 N-(m-methylphenyl)-N'-phenylthiourea 
• 22937-96-8 1-(4-nitro-phenyl)-3-m-tolyl-thiourea 

Downstream Products

• 97829-79-3 N,N'-bis-(2,4-dioxo-3-m-tolyl-thiazolidin-5-yl)-2,2'-piperazine-1,4-diyl-bis-acetamide 
• 92696-04-3 5-(2-chloro-acetylamino)-3-m-tolyl-thiazolidine-2,4-dione 
• 91818-39-2 5-amino-3-m-tolyl-thiazolidine-2,4-dione 
• 94462-06-3 N,N-diethyl-glycine 2,4-dioxo-3-m-tolyl-thiazolidin-5-ylamide 
• 94066-29-2 m-tolyl-thiazolidinetrione 5-phenylhydrazone 

Relevant academic research and scientific papers

A convenient approach to synthesize substituted 5-Arylidene-3-m-tolyl thiazolidine-2, 4-diones by using morpholine as a catalyst and its theoretical study

Thiazolidinediones are very important and used as a drug for the treatment of type 2 diabetes. Here, we report a convenient approach to synthesis 3-m-tolyl-5-arylidene-2,4-thiazolidi-nediones (TZDs) derivatives 7a-e in two steps with moderate to good yield using morpholine as a catalyst. All the structures were confirmed by their spectral IR, 1H NMR and 13C NMR data. The anti-diabatic activity of all synthesized molecules is evaluated by docking with peroxisome proliferator-activated receptor-γ (PPARγ). Preliminary flexible docking studies reveals that our compounds 7a, 7d and 7e showed better binding affinity with the protein and could be a potential candidate for the treatment of type 2 diabetes in near future.